ATE460939T1 - Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern - Google Patents

Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern

Info

Publication number: ATE460939T1
Authority: AT; Austria
Prior art keywords: testosterone; treating; kits; compositions; combinations
Prior art date: 2000-08-30

Application number

AT01966486T

Other languages

English (en)

Inventor

Robert Dudley

Original Assignee

Unimed Pharmaceuticals Llc

Besins Int Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-30

Filing date

2001-08-29

Publication date

2010-04-15

2000-08-30 Priority claimed from US09/651,777 external-priority patent/US6503894B1/en

2001-08-29 Application filed by Unimed Pharmaceuticals Llc, Besins Int Lab filed Critical Unimed Pharmaceuticals Llc

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE460939T1 publication Critical patent/ATE460939T1/de

Links

MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 12
229960003604 testosterone Drugs 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 4
241000124008 Mammalia Species 0.000 abstract 3
230000002950 deficient Effects 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
239000008177 pharmaceutical agent Substances 0.000 abstract 2
150000003431 steroids Chemical class 0.000 abstract 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 abstract 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
229960001566 methyltestosterone Drugs 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Emergency Medicine (AREA)

AT01966486T 2000-08-30 2001-08-29 Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern ATE460939T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/651,777 US6503894B1 (en)	2000-08-30	2000-08-30	Pharmaceutical composition and method for treating hypogonadism
US70375300A	2000-11-01	2000-11-01
PCT/US2001/027205 WO2002017927A1 (en)	2000-08-30	2001-08-29	Method for treating erectile dysfunction and increasing libido in men

Publications (1)

Publication Number	Publication Date
ATE460939T1 true ATE460939T1 (de)	2010-04-15

Family

ID=27096141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01966486T ATE460939T1 (de)	2000-08-30	2001-08-29	Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern

Country Status (22)

Country	Link
US (1)	US20050054623A1 (de)
EP (2)	EP1315502B1 (de)
JP (1)	JP2004524267A (de)
KR (1)	KR100861603B1 (de)
CN (1)	CN1473047A (de)
AT (1)	ATE460939T1 (de)
AU (2)	AU2001286995B2 (de)
BR (1)	BR0113651A (de)
CA (2)	CA2420895C (de)
CY (1)	CY1110085T1 (de)
DE (1)	DE60141587D1 (de)
DK (1)	DK1315502T3 (de)
ES (1)	ES2341090T3 (de)
IL (1)	IL154692A0 (de)
MX (1)	MXPA03001858A (de)
NO (1)	NO332649B1 (de)
NZ (1)	NZ524601A (de)
PL (1)	PL205279B1 (de)
PT (1)	PT1315502E (de)
SI (1)	SI1315502T1 (de)
TR (1)	TR200300776T2 (de)
WO (1)	WO2002017927A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN814496A0 (en)	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
JP5039252B2 (ja) *	2000-08-31	2012-10-03	ユニメッドファーマシューティカルズ，リミティドライアビリティカンパニー	性機能低下を治療するための医薬組成物及び方法
MY139721A (en)	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
CA2489865C (en)	2002-06-25	2012-05-08	Acrux Dds Pty Ltd	Transdermal delivery rate control using amorphous pharmaceutical compositions
AUPS317302A0 (en) *	2002-06-25	2002-07-18	Drug Delivery Solutions Pty Ltd	Metastable pharmaceutical compositions
IL152573A (en)	2002-10-31	2009-11-18	Transpharma Medical Ltd	A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en)	2002-10-31	2008-12-29	Transpharma Medical Ltd	A skin-to-skin transmission system of water-insoluble drugs
US8883769B2 (en)	2003-06-18	2014-11-11	White Mountain Pharma, Inc.	Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en)	2003-06-18	2004-12-23	White Hillary D.	Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
NZ551356A (en)	2004-05-11	2009-09-25	Emotional Brain Bv	Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1634583A1 (de) *	2004-09-09	2006-03-15	Laboratoires Besins International	Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
KR20130114229A (ko)	2005-06-03	2013-10-16	애크럭스 디디에스 피티와이 리미티드	경피 약물 전달 방법 및 조성물
WO2006128255A1 (en) *	2005-06-03	2006-12-07	Acrux Dds Pty Ltd	Method and composition for transdermal drug delivery
US20070065494A1 (en) *	2005-08-03	2007-03-22	Watson Laboratories, Inc.	Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
DK2450041T3 (en)	2005-10-12	2018-11-19	Unimed Pharmaceuticals Llc	Enhanced testosterone gel for use in the treatment of hypogonadism
EP1790343A1 (de)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
US8613360B2 (en)	2006-09-29	2013-12-24	M-I L.L.C.	Shaker and degasser combination
EP1925307A1 (de)	2006-11-03	2008-05-28	Emotional Brain B.V.	Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
GB2461725B (en)	2008-07-10	2012-06-13	United Wire Ltd	Improved sifting screen
US20100022494A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20110190201A1 (en) *	2008-07-24	2011-08-04	Searete Llc	Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022991A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System and device for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) *	2008-07-24	2010-03-11	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
MY169998A (en)	2010-05-12	2019-06-19	Pomerleau Mech Inc	Systems and methods for drying drill cuttings
RU2474424C2 (ru) *	2010-09-24	2013-02-10	Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
AU2011329782A1 (en)	2010-11-18	2013-06-20	White Mountain Pharma, Inc.	Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9795639B1 (en)	2013-03-16	2017-10-24	BioDlogics, LLC	Methods for the treatment of erectile dysfunction by human birth tissue material compostion
US8785426B1 (en)	2013-12-13	2014-07-22	Upsher-Smith Laboratories, Inc.	Testosterone gel compositions and related methods
PT3710012T (pt) *	2018-02-02	2025-09-08	Acerus Biopharma Inc	Métodos de terapia com testosterona
JP7515582B2 (ja)	2019-11-06	2024-07-12	スマーテックトピカル，インコーポレイテッド	シクロオキシゲナーゼ阻害剤の局所配合剤およびその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4496556A (en) *	1982-08-16	1985-01-29	Norman Orentreich	Topical applications for preventing dry skin
US4855305A (en) *	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
US5152997A (en) *	1990-12-11	1992-10-06	Theratech, Inc.	Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
TW224048B (de) *	1992-03-30	1994-05-21	Hoechst Roussel Pharma
WO1993025168A1 (en) *	1992-06-11	1993-12-23	Theratech, Inc.	The use of glycerin in moderating transdermal drug delivery
US5776923A (en) *	1993-01-19	1998-07-07	Endorecherche, Inc.	Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5698589A (en) *	1993-06-01	1997-12-16	International Medical Innovations, Inc.	Water-based topical cream containing nitroglycerin and method of preparation and use thereof
JP4036496B2 (ja) *	1995-10-24	2008-01-23	リンテック株式会社	ゲル製剤の製造方法
AUPN814496A0 (en) *	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
US5730987A (en) *	1996-06-10	1998-03-24	Omar; Lotfy Ismail	Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
DE19701949A1 (de) *	1997-01-13	1998-07-16	Jenapharm Gmbh	Transdermales therapeutisches System
GB9700878D0 (en) *	1997-01-17	1997-03-05	Scherer Ltd R P	Dosage forms and method for ameliorating male erectile dysfunction
CN1250373A (zh) *	1997-02-07	2000-04-12	瑟垃技术有限公司	用于在具有睾酮缺乏症状的妇女中补充睾酮的组合物和方法
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ATE418988T1 (de) *	1997-11-10	2009-01-15	Strakan Int Ltd	Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
DE69927154T2 (de) *	1998-06-25	2006-06-29	Lavipharm Laboratories, Inc.	Vorrichtung und verfahren zur behandlung von erektionsstörungen
JP2000225116A (ja) *	1998-12-04	2000-08-15	Eisai Co Ltd	陰茎径の測定法
JP2000212080A (ja) *	1999-01-26	2000-08-02	Hiroshi Azuma	勃起機能不全改善剤
DE19903087A1 (de) *	1999-01-27	2000-08-10	Forssmann Wolf Georg	Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
RO121628B1 (ro) *	1999-02-05	2008-01-30	Cipla Limited	Compoziţie medicinală, topică, pulverizabilă,dozator care o conţine, procedeu de realizare a dozatorului şi utilizarea compoziţiei menţionate
US6087362A (en) *	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition

2001
- 2001-08-29 PT PT01966486T patent/PT1315502E/pt unknown
- 2001-08-29 PL PL366037A patent/PL205279B1/pl unknown
- 2001-08-29 CN CNA018172660A patent/CN1473047A/zh active Pending
- 2001-08-29 BR BR0113651-8A patent/BR0113651A/pt not_active Application Discontinuation
- 2001-08-29 EP EP01966486A patent/EP1315502B1/de not_active Expired - Lifetime
- 2001-08-29 JP JP2002522900A patent/JP2004524267A/ja active Pending
- 2001-08-29 KR KR1020037003148A patent/KR100861603B1/ko not_active Expired - Lifetime
- 2001-08-29 AU AU2001286995A patent/AU2001286995B2/en not_active Expired
- 2001-08-29 SI SI200130964T patent/SI1315502T1/sl unknown
- 2001-08-29 DE DE60141587T patent/DE60141587D1/de not_active Expired - Lifetime
- 2001-08-29 CA CA002420895A patent/CA2420895C/en not_active Expired - Lifetime
- 2001-08-29 IL IL15469201A patent/IL154692A0/xx active IP Right Grant
- 2001-08-29 EP EP10184108A patent/EP2283865A1/de not_active Withdrawn
- 2001-08-29 TR TR2003/00776T patent/TR200300776T2/xx unknown
- 2001-08-29 AU AU8699501A patent/AU8699501A/xx active Pending
- 2001-08-29 ES ES01966486T patent/ES2341090T3/es not_active Expired - Lifetime
- 2001-08-29 WO PCT/US2001/027205 patent/WO2002017927A1/en not_active Ceased
- 2001-08-29 MX MXPA03001858A patent/MXPA03001858A/es active IP Right Grant
- 2001-08-29 DK DK01966486.1T patent/DK1315502T3/da active
- 2001-08-29 NZ NZ524601A patent/NZ524601A/en not_active IP Right Cessation
- 2001-08-29 AT AT01966486T patent/ATE460939T1/de active
- 2001-08-29 CA CA2746787A patent/CA2746787A1/en not_active Abandoned
2003
- 2003-02-28 NO NO20030955A patent/NO332649B1/no not_active IP Right Cessation
2004
- 2004-02-25 US US10/787,071 patent/US20050054623A1/en not_active Abandoned
2010
- 2010-06-15 CY CY20101100550T patent/CY1110085T1/el unknown

Also Published As

Publication number	Publication date
AU8699501A (en)	2002-03-13
NO20030955L (no)	2003-04-28
EP1315502B1 (de)	2010-03-17
CA2420895A1 (en)	2002-03-07
BR0113651A (pt)	2004-11-09
PT1315502E (pt)	2010-05-06
PL205279B1 (pl)	2010-03-31
NZ524601A (en)	2006-04-28
EP1315502A1 (de)	2003-06-04
US20050054623A1 (en)	2005-03-10
NO332649B1 (no)	2012-11-26
CN1473047A (zh)	2004-02-04
JP2004524267A (ja)	2004-08-12
CA2746787A1 (en)	2002-03-07
CY1110085T1 (el)	2015-01-14
AU2001286995B2 (en)	2006-11-30
SI1315502T1 (sl)	2010-07-30
PL366037A1 (en)	2005-01-24
KR100861603B1 (ko)	2008-10-07
EP2283865A1 (de)	2011-02-16
CA2420895C (en)	2007-03-13
MXPA03001858A (es)	2004-05-21
ES2341090T3 (es)	2010-06-15
DE60141587D1 (de)	2010-04-29
NO20030955D0 (no)	2003-02-28
DK1315502T3 (da)	2010-07-19
TR200300776T2 (tr)	2005-10-21
IL154692A0 (en)	2003-09-17
WO2002017927A1 (en)	2002-03-07
KR20030043949A (ko)	2003-06-02

Legal Events

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1315502

Country of ref document: EP

Publication	Publication Date	Title
ATE460939T1 (de)	2010-04-15	Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
MXPA03001859A (es)	2004-05-21	Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
BR0316203A (pt)	2005-10-04	Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
CL2004000026A1 (es)	2005-02-04	Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BR0215254A (pt)	2005-02-01	Composições e métodos para intensificar a liberação de corticoesteróides
DK0462189T3 (da)	1995-11-20	Kombinationsterapi til behandling af østrogenfølsomme sygdomme
DE69432990D1 (de)	2003-09-04	PROGESTAGEN-FREIE FORMULIERUNGEN VON GnRH UND ESTROGEN ZUR BEHANDLUNG VON BENIGNEN GYNÄKOLOGISCHEN STÖRUNGEN
DE69525847D1 (de)	2002-04-18	Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
EA200201000A1 (ru)	2003-02-27	Гормон-заместительная терапия
ATE324106T1 (de)	2006-05-15	Zusammensetzungen und verfahren zur regulierung des serumcholesterins
BR9807828A (pt)	2000-03-08	Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona
DE60139634D1 (de)	2009-10-01	Kombination von einem östrogen und einem androgen zur behandlung von hormonmangel in der östrogenersatztherapie für frauen
BR0110208A (pt)	2003-01-28	Composições e terapias para distúrbios associados com hiperlipidemia
BR0308584A (pt)	2005-02-22	Composição farmacêutica androgênica e método para tratamento de depressão
DE60115274D1 (de)	2005-12-29	Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
BR0214643A (pt)	2004-11-03	Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
HUP9901505A2 (hu)	1999-09-28	Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
MX2020011341A (es)	2020-11-24	Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos.
PL360669A1 (en)	2004-09-20	4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
AR038904A1 (es)	2005-02-02	Metodo para incrementar en la mujer las concentraciones de testosterona y esteroides relacionados
DE502004004976D1 (de)	2007-10-25	Verwendung eines oxytocin und testosteron oder estradiol enthaltenden gemisches zur behandlung von störungen des psychosozialen erlebens und verhaltens
HRP20070360A2 (hr)	2008-12-31	Drospirenon za hormonsku nadomjesnu terapiju